

# **CANCER-RELATED FATIGUE**

### **CLINICAL CASE DISCUSSION**

### **Fausto Roila**

Medical Oncology Division
Azienda Ospedaliera di Perugia
Perugia, Italy

### **DISCLOSURE**

Personal financial interests: NO DISCLOSURES TO DECLARE

#### Institutional financial interests:

- TERNI Hospital: Novartis-GSK, Merck Sharp & Dohme, Roche, Bristol-Myers Squibb, Boehringher Ingelheim, Sanofi-Aventis, Pfizer, Astra Zeneca, Astellas, Eli Lilly, Helsinn
- PERUGIA Hospital: Novartis-GSK, Merck Sharp & Dohme, Roche, Bristol-Myers
   Squibb, Boehringher Ingelheim, IPSEN, Astra Zeneca

### Non-financial interests: leadership role in any other medical society

President of the NICSO (Italian Network for Supportive Care in Oncology) from June 2014 to June 2017; Vice-President from June 2017 to June 2020



### CASE PRESENTATION

- Patient with non-small cell lung cancer (T3, N0, M0, stage IIB) submitted to 4 cycles of adjuvant chemotherapy with cisplatin/vinorelbine
- 3 months after the end of chemotherapy the patient presented fatigue which strongly ameliorate with physical exercise, psycoeducation and psycooncological support





# **FATIGUE: DEFINITION**

Cancer-related fatigue (CRF) is a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer and/or cancer treatment that is not proportional to recent activity and interferes with usual functioning

In comparison to the fatigue experienced by healthy individuals, CRF is often not alleviated by rest or sleep





# **CRF: INCIDENCE**


CRF can occur before, during and even long after anticancer treatment has been completed

- up to 40% of patients report CRF at diagnosis
- 80% and 90% of patients during chemotherapy and radiotherapy, respectively
- 17%-21% or 33%-53% of patients when strict criteria or other criteria are applied, respectively, in the posttreatment phase



# **CRF: SCREENING AND DIAGNOSIS**

- All cancer patients should be routinely screened for the presence and severity of fatigue from the point of diagnosis onward, at regular intervals during therapy and aftercare and if clinically indicated (level of evidence II, grade of recommendation B)
- Screening should be done using brief and validated tools with established cut-off values for severity (e.g., Numerical Rating Scale) (level of evidence II, grade of recommendation B)



# **CRF: SCREENING AND DIAGNOSIS**

 Patients who screen positive for CRF (values of 4 out 10 or higher indicating moderate to severe fatigue) should undergo a comprehensive and focused assessment with the aim to identify treatable contributing issues and comorbid conditions (level of

evidence II, grade of recommendation B)

 The Brief Fatigue Inventory (BFI, a reliable and easily understood questionnaire, validated in many languages, in clinical screening and research) integrates the assessment of fatigue severity and its impact on important functional domains



HOSPITAL #

# **CRF: SCREENING AND DIAGNOSIS**

- the comprehensive and focused assessment should involve:
  - a focused fatigue history
  - a thorough physical examination
  - a status of the underlying malignant disease
  - a review of body systems
  - a mental status examination
  - a minimum battery of laboratory tests

(level of evidence II, grade of recommendation B)



# **CRF: CONTRIBUTING ISSUES**

### ANAEMIA

### SYMPTOM BURDEN

Pain, anxiety, depression, dyspnoea, sleep dysfunction

### MEDICAL COMORBIDITIES

Endocrinopathies (hypothyroidism, hypogonadism, diabetes mellitus), cardiopulmonary disorders, hepatic, renal and neurological dysfunctions, adrenal insufficiency, infections



# **CRF: CONTRIBUTING ISSUES**

### NUTRITIONAL AND FLUID IMBALANCES

Weight loss, changes in caloric intake, fluid and electrolyte imbalances, gastrointestinal tract motility disorders

### MEDICATIONS

 Opioids, sedating agents (hypnotics, neuropathic agents, antihistamines), beta blockers

### CANCER THERAPY

 Chemotherapy, radiotherapy, surgery, immunotherapy, hormone therapy, molecularly targeted agents



# **CRF: TREATMENT**

PHARMACOLOGICAL TREATMENT

- NON-PHARMACOLOGICAL INTERVENTIONS
  - PHYSICAL EXERCISE
  - PSYCHOSOCIAL TREATMENT
  - MIND-BODY INTERVENTIONS







# PHARMACOLOGICAL TREATMENTS



### Not recommended

#### PSYCHOSTIMULANTS

Methylphenidate, modafinil

[II, D]

Dexmethylphenidate, dexamphetamine, long-acting methylphenidate,

[II, D]

armodafinil

#### ANTIDEPRESSANTS

Paroxetine

[II, D]

#### ACETHYLCHOLINE INHIBITORS

Donepezil

[II, D]

#### OTHER DRUGS

Eszopiclone, TRH, megestrol, ATP, melatonin

[II, D]





# PHARMACOLOGICAL TREATMENTS

## Not recommended

### NUTRICEUTICAL INTERVENTIONS



Wisconsin ginseng [II, D]

L-carnitine [II, D]

Coenzyme Q10 [II, D]

Astagalus, guarana, mistletoe [II, D]





# PHARMACOLOGICAL TREATMENTS

## Recommended



### CORTICOSTEROIDS

Dexamethasone, methylprednisolone
 (for short-term use in the advanced cancer patients)

[II, B]



# NON-PHARMACOLOGICAL INTERVENTIONS

PHYSICAL EXERCISE

- PSYCHOSOCIAL TREATMENT
- MIND-BODY INTERVENTIONS
  - Mindfulness-based stress reduction
  - Yoga
  - Acupuncture



# PHYSICAL EXERCISE

- The role of physical exercise in patients with CRF during both active treatment and for those who have completed treatment has been documented by multiple systematic reviews and meta-analyses.
- Despite much evidence for exercise an exact exercise prescription in patients with CRF does not exist.
- Some guidelines encourage 150 minutes of moderate aerobic exercise, such as fast walking, cycling, or swimming, per week with an additional 2 to 3 days per week of strength training such as weight lifting unless contraindicated (e.g., extensive lytic bone metastases, fever or infection).



# NON-PHARMACOLOGICAL INTERVENTIONS

## Recommended

### PHYSICAL EXERCISE



Moderate intensity, aerobic and functional resistance exercise is recommended in patients with CRF [I, B]

Aerobic, resistance and moderate physical exercise in patients with CRF provides symptomatic relief in depression, anxiety, pain, and muscle strength [II,B]



# **PSYCHOSOCIAL TREATMENT**

 Information on the multi-factorial nature of CRF and its potential causes and influencing factors should be given

 Counseling should include recommendations for energy preservation, task prioritisation, activity pacing and advice on how to delegate less important activities (may be supported by brochures or interactive media)



# **PSYCHOSOCIAL TREATMENT**

- Psychoeducation may be helpful for patients to identify sources of psychosocial distress and to eliminate stress-producing activities when possible and to find a balance between rest and activity during the day (using diary techniques, including subjective rating of each activity in terms of the perceived level of fatigue).
- Cognitive behavioral therapy is generally used to address the following factors: coping with the experience of cancer; fear of disease recurrence; dysfunctional thoughts and beliefs regarding fatigue, sleep dysregulation, etc.



# NON-PHARMACOLOGICAL INTERVENTIONS

### Recommended



### PSYCHOSOCIAL TREATMENT

- ✓ information and counseling to educate cancer patients about ways to prevent fatigue are recommended [II,B]
- psychoeducation is recommended to help patients to identify source of psychosocial distress and to eliminate stress producing activities [II,B]
- ✓ cognitive-behavioral therapy is recommended to improve CRF [II,B]



# NON-PHARMACOLOGICAL INTERVENTIONS

### not recommended

### MIND-BODY INTERVENTION



Mindfulness-based stress reduction


[II, D]

Yoga

[II, C]

Acupuncture

[II, D]





# Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †

A. Fabi<sup>1</sup>, R. Bhargava<sup>2</sup>, S. Fatigoni <sup>3</sup>, M. Guglielmo <sup>4</sup>, M. Horneber<sup>5</sup>, F. Roila<sup>3</sup>, J. Weis<sup>6</sup>, K. Jordan<sup>7</sup> & C. I. Ripamonti<sup>4</sup>, on behalf of the ESMO Guidelines Committee\*

<sup>1</sup>Division of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy; <sup>2</sup>William Osler Health System, Corporate Research Department, Department of Oncology and Division of Palliative Care, Ottawa, Canada; <sup>3</sup>Division of Medical Oncology, Ospedale Santa Maria della Misericordia, Perugia; <sup>4</sup>Oncology-Supportive Care Unit, Department Onco-Haematology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy; <sup>5</sup>Department of Internal Medicine, Division of Oncology and Hematology Paracelsus Medical University, Klinikum Nuremberg, Nuremberg; <sup>6</sup>Department of Self Help Research in Oncology, Comprehensive Cancer Center, University Medical Center, Freiburg; <sup>7</sup>Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Germany.

\*Correspondence to: ESMO Guidelines Committee, ESMO Head Office, Via Ginevra 4, 6900 Lugano, Switzerland. E-mail: <a href="mailto:clinicalguidelines@esmo.org">clinicalguidelines@esmo.org</a>

†Approved by the ESMO Guidelines Committee: July 2019.

Manuscript under review for submission to Annals of Oncology October 2019



# Thank you

